Cargando…
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
OBJECTIVE. Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intrap...
Autores principales: | Pitiyarachchi, Omali, Friedlander, Michael, Java, James J., Chan, John K., Armstrong, Deborah K., Markman, Maurie, Herzog, Thomas J., Monk, Bradley J., Backes, Floor, Alvarez Secord, Angeles, Bonebrake, Albert, Rose, Peter G., Tewari, Krishnansu S., Lentz, Samuel S., Geller, Melissa A., Copeland, Larry J., Mannel, Robert S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718158/ https://www.ncbi.nlm.nih.gov/pubmed/35835612 http://dx.doi.org/10.1016/j.ygyno.2022.07.004 |
Ejemplares similares
-
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009) -
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Where Do We Go From Here?
por: Markman, Maurie
Publicado: (2016) -
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020) -
Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
por: Ko, Jieun, et al.
Publicado: (2021) -
Comment on: hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
por: Venkatappa, Shalini, et al.
Publicado: (2022)